Comparative Pharmacokinetic Study Among 3 Metformin Formulations in Healthy Mexican Volunteers: A Single-Dose, Randomized, Open-Label, 3-Period Crossover Study

Type 2 diabetes mellitus is the most common form of diabetes. Metformin is a first-line drug for its treatment. In Mexico, there are 34 generic formulations of metformin, so brand-generic substitutions and generic-generic substitutions are a common practice. Generic products are compared only with t...

Descripción completa

Detalles Bibliográficos
Autores principales: Montoya Eguía, Sandra Lucía, Garza Ocañas, Lourdes, Badillo Castañeda, Christian Tadeo, Tamez de la O, Eduardo Javier, Zanatta Calderón, María Teresa, Gómez Meza, Marco Vinicio, Garza Ulloa, Humberto Jesús
Formato: Artículo
Lenguaje:inglés
Publicado: 2015
Acceso en línea:http://eprints.uanl.mx/14977/1/136.pdf
_version_ 1824414210095841280
author Montoya Eguía, Sandra Lucía
Garza Ocañas, Lourdes
Badillo Castañeda, Christian Tadeo
Tamez de la O, Eduardo Javier
Zanatta Calderón, María Teresa
Gómez Meza, Marco Vinicio
Garza Ulloa, Humberto Jesús
author_facet Montoya Eguía, Sandra Lucía
Garza Ocañas, Lourdes
Badillo Castañeda, Christian Tadeo
Tamez de la O, Eduardo Javier
Zanatta Calderón, María Teresa
Gómez Meza, Marco Vinicio
Garza Ulloa, Humberto Jesús
author_sort Montoya Eguía, Sandra Lucía
collection Repositorio Institucional
description Type 2 diabetes mellitus is the most common form of diabetes. Metformin is a first-line drug for its treatment. In Mexico, there are 34 generic formulations of metformin, so brand-generic substitutions and generic-generic substitutions are a common practice. Generic products are compared only with their brand-name equivalents and not with the same product made by other manufacturers. Objective: Our aim was to establish whether 2 generic formulations of 500 mg metformin available on the Mexican market fulfill the criteria for interchangeability. Methods: This single-dose, randomized-sequence, open-label, 3-period crossover study was conducted in 12 healthy subjects in compliance with the Declaration of Helsinki and International Conference on Harmonization guidelines. A validated HPLC procedure coupled with a spectrum mass detector were used to analyze the metformin concentration in plasma samples. All pharmacokinetic analyses were performed using WinNonlin Professional Software version 6.3 (Pharsight Corporation, Sunnyvale, California). Results: Twelve healthy Mexican volunteers were enrolled in the study. Their mean age was 24.33 years and mean weight was 62.54 kg. The mean body mass index was 23.02. The values obtained for the test and reference formulations were: Cmax 1163.5 (295.2) ng/mL for treatment A, 1184.6 (215.0) ng/mL for treatment B, and 1167.8 (176.8) ng/mL for treatment C. AUC0–t was 6240.7 (1629.4) ng/mL/h for treatment A, 6433.7 (1249.8) ng/mL/h for treatment B, and 6567.1 (1145.5) ng/mL/h for treatment C. AUC0–1 was 6837.3 (1618.5) ng/mL/h for treatment A, 6911.8 (1178.4) ng/mL/h for treatment B, and 7178.6 (1086.8) ng/mL/h for treatment C. Conclusions: The test formulation 500-mg metformin tablets were bioequivalent to the reference formulation and to each other, according to the general laws of health care in Mexico.
format Article
id eprints-14977
institution UANL
language English
publishDate 2015
record_format eprints
spelling eprints-149772019-06-26T18:34:00Z http://eprints.uanl.mx/14977/ Comparative Pharmacokinetic Study Among 3 Metformin Formulations in Healthy Mexican Volunteers: A Single-Dose, Randomized, Open-Label, 3-Period Crossover Study Montoya Eguía, Sandra Lucía Garza Ocañas, Lourdes Badillo Castañeda, Christian Tadeo Tamez de la O, Eduardo Javier Zanatta Calderón, María Teresa Gómez Meza, Marco Vinicio Garza Ulloa, Humberto Jesús Type 2 diabetes mellitus is the most common form of diabetes. Metformin is a first-line drug for its treatment. In Mexico, there are 34 generic formulations of metformin, so brand-generic substitutions and generic-generic substitutions are a common practice. Generic products are compared only with their brand-name equivalents and not with the same product made by other manufacturers. Objective: Our aim was to establish whether 2 generic formulations of 500 mg metformin available on the Mexican market fulfill the criteria for interchangeability. Methods: This single-dose, randomized-sequence, open-label, 3-period crossover study was conducted in 12 healthy subjects in compliance with the Declaration of Helsinki and International Conference on Harmonization guidelines. A validated HPLC procedure coupled with a spectrum mass detector were used to analyze the metformin concentration in plasma samples. All pharmacokinetic analyses were performed using WinNonlin Professional Software version 6.3 (Pharsight Corporation, Sunnyvale, California). Results: Twelve healthy Mexican volunteers were enrolled in the study. Their mean age was 24.33 years and mean weight was 62.54 kg. The mean body mass index was 23.02. The values obtained for the test and reference formulations were: Cmax 1163.5 (295.2) ng/mL for treatment A, 1184.6 (215.0) ng/mL for treatment B, and 1167.8 (176.8) ng/mL for treatment C. AUC0–t was 6240.7 (1629.4) ng/mL/h for treatment A, 6433.7 (1249.8) ng/mL/h for treatment B, and 6567.1 (1145.5) ng/mL/h for treatment C. AUC0–1 was 6837.3 (1618.5) ng/mL/h for treatment A, 6911.8 (1178.4) ng/mL/h for treatment B, and 7178.6 (1086.8) ng/mL/h for treatment C. Conclusions: The test formulation 500-mg metformin tablets were bioequivalent to the reference formulation and to each other, according to the general laws of health care in Mexico. 2015 Article PeerReviewed text en cc_by_nc_nd http://eprints.uanl.mx/14977/1/136.pdf http://eprints.uanl.mx/14977/1.haspreviewThumbnailVersion/136.pdf Montoya Eguía, Sandra Lucía y Garza Ocañas, Lourdes y Badillo Castañeda, Christian Tadeo y Tamez de la O, Eduardo Javier y Zanatta Calderón, María Teresa y Gómez Meza, Marco Vinicio y Garza Ulloa, Humberto Jesús (2015) Comparative Pharmacokinetic Study Among 3 Metformin Formulations in Healthy Mexican Volunteers: A Single-Dose, Randomized, Open-Label, 3-Period Crossover Study. Current Therapeutic Research, 77. pp. 18-23. ISSN 0011393X http://doi.org/10.1016/j.curtheres.2014.09.003 doi:10.1016/j.curtheres.2014.09.003
spellingShingle Montoya Eguía, Sandra Lucía
Garza Ocañas, Lourdes
Badillo Castañeda, Christian Tadeo
Tamez de la O, Eduardo Javier
Zanatta Calderón, María Teresa
Gómez Meza, Marco Vinicio
Garza Ulloa, Humberto Jesús
Comparative Pharmacokinetic Study Among 3 Metformin Formulations in Healthy Mexican Volunteers: A Single-Dose, Randomized, Open-Label, 3-Period Crossover Study
thumbnail https://rediab.uanl.mx/themes/sandal5/images/online.png
title Comparative Pharmacokinetic Study Among 3 Metformin Formulations in Healthy Mexican Volunteers: A Single-Dose, Randomized, Open-Label, 3-Period Crossover Study
title_full Comparative Pharmacokinetic Study Among 3 Metformin Formulations in Healthy Mexican Volunteers: A Single-Dose, Randomized, Open-Label, 3-Period Crossover Study
title_fullStr Comparative Pharmacokinetic Study Among 3 Metformin Formulations in Healthy Mexican Volunteers: A Single-Dose, Randomized, Open-Label, 3-Period Crossover Study
title_full_unstemmed Comparative Pharmacokinetic Study Among 3 Metformin Formulations in Healthy Mexican Volunteers: A Single-Dose, Randomized, Open-Label, 3-Period Crossover Study
title_short Comparative Pharmacokinetic Study Among 3 Metformin Formulations in Healthy Mexican Volunteers: A Single-Dose, Randomized, Open-Label, 3-Period Crossover Study
title_sort comparative pharmacokinetic study among 3 metformin formulations in healthy mexican volunteers a single dose randomized open label 3 period crossover study
url http://eprints.uanl.mx/14977/1/136.pdf
work_keys_str_mv AT montoyaeguiasandralucia comparativepharmacokineticstudyamong3metforminformulationsinhealthymexicanvolunteersasingledoserandomizedopenlabel3periodcrossoverstudy
AT garzaocanaslourdes comparativepharmacokineticstudyamong3metforminformulationsinhealthymexicanvolunteersasingledoserandomizedopenlabel3periodcrossoverstudy
AT badillocastanedachristiantadeo comparativepharmacokineticstudyamong3metforminformulationsinhealthymexicanvolunteersasingledoserandomizedopenlabel3periodcrossoverstudy
AT tamezdelaoeduardojavier comparativepharmacokineticstudyamong3metforminformulationsinhealthymexicanvolunteersasingledoserandomizedopenlabel3periodcrossoverstudy
AT zanattacalderonmariateresa comparativepharmacokineticstudyamong3metforminformulationsinhealthymexicanvolunteersasingledoserandomizedopenlabel3periodcrossoverstudy
AT gomezmezamarcovinicio comparativepharmacokineticstudyamong3metforminformulationsinhealthymexicanvolunteersasingledoserandomizedopenlabel3periodcrossoverstudy
AT garzaulloahumbertojesus comparativepharmacokineticstudyamong3metforminformulationsinhealthymexicanvolunteersasingledoserandomizedopenlabel3periodcrossoverstudy